Royalty Pharma Sees FY23 Adjusted Cash Receipts (non-GAAP) To Be $2.90B-$2.975B (Prior Guidance: $2.850B-$2.950B)
Portfolio Pulse from Benzinga Newsdesk
Royalty Pharma Plc (NASDAQ:RPRX) has updated its FY23 adjusted cash receipts guidance to $2.90B-$2.975B, up from the previous guidance of $2.850B-$2.950B. This represents an underlying growth of 6% to 10% prior to the Zavzpret milestone payment in Q1 2023 and the payments related to the Biohaven Preferred Shares received in 2022.
August 08, 2023 | 11:15 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Royalty Pharma's updated FY23 guidance indicates a potential increase in revenue, which could positively impact the company's stock price.
The updated guidance from Royalty Pharma indicates a potential increase in their revenue for FY23. This news is likely to be viewed positively by investors, which could lead to an increase in demand for the company's shares and, consequently, a rise in its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100